Narayana Hrudayalaya Q2 Profit Rises to Rs 301 Crore, Revenue Jumps

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Narayana Hrudayalaya Q2 Profit Rises to Rs 301 Crore, Revenue Jumps

Narayana Hrudayalaya reported a significant surge in consolidated revenue to Rs 2,843.99 crore for the September 2026 quarter. Net profit rose to Rs 301.03 crore, reflecting strong year-on-year growth in its healthcare operations. Meanwhile, corporate restructuring via the merger of MMRHL and demerger of NHIC remains in progress awaiting final NCLT orders.

Narayana Hrudayalaya Q2 Results: Revenue Hits Rs 2,844 Crore

Narayana Hrudayalaya reported a consolidated quarterly revenue of Rs 2,843.99 crore, up from Rs 1,643.79 crore in the same period last year. Net profit attributable to owners climbed to Rs 301.03 crore, compared to Rs 258.37 crore reported in the year-ago quarter.

Reader Takeaway: Strong revenue expansion drives bottom-line growth, while pending NCLT-led restructuring processes remain key focus areas for stakeholders.

What just happened

Narayana Hrudayalaya announced its financial results for the quarter ended September 30, 2026. The board approved both standalone and consolidated unaudited figures. Statutory auditors, Deloitte Haskins & Sells LLP, provided an unmodified review opinion on these results.

Why this matters

The company demonstrated substantial year-on-year growth. Consolidated revenue grew sharply from Rs 1,643.79 crore to Rs 2,843.99 crore. Standalone operations also improved, with revenue rising to Rs 1,185.38 crore and net profit increasing to Rs 175.63 crore from Rs 137.88 crore in the corresponding period of the previous year.

Corporate Developments

The hospital chain is currently undergoing two major structural changes. The merger of Meridian Medical Research & Hospital Ltd (MMRHL) is in the final stages, with petitions filed at the NCLT. Similarly, the demerger of clinical services from NH Integrated Care Private Limited (NHIC) into the company is also awaiting final NCLT approval. The company clarified that these structural changes did not impact the reported financial results for this quarter.

What to track next

Investors should look for the final NCLT orders regarding the MMRHL merger and the NHIC demerger. These developments are expected to streamline the company's organizational structure, though the firm currently continues to focus solely on its 'Medical and Healthcare Related Services' segment.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.